AnalystsKumaraguru RajaKumaraguru Raja's Stock Forecasts
AnalystsKumaraguru Raja
Sectors:
Analyst Ranking
Bottom 1%
#4202 out of 4241 analysts
Average Return
-62.79%
Win Rate
7%1 out of 14
Risk vs Reward
Poor
Good
Kumaraguru Raja's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Atyr Pharma IncLIFE | +1.85% | $2.16 | $2.20 | 2023-03-06 - 2023-06-09 | Strong Buy |
Kumaraguru Raja Analyst Color
Get additional color on Kumaraguru Raja's coverage of popular stocks
Kumaraguru Raja's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Atyr Pharma IncLIFE | 1 | Strong Buy | $9.00 | +309.09% | Reinstates | 3 months ago |
Rain Oncology IncRAIN | 1 | Strong Buy | $21.00 | +1,607.32% | Reinstates | 4 months ago |
Apexigen IncAPGN | 1 | Strong Buy | $15.00 | +3,057.89% | Reinstates | 5 months ago |
Monopar TherapeuticsMNPR | 2 | Strong Buy | $18.00 | +1,814.89% | Reinstates | 6 months ago |
Veru IncVERU | 1 | Strong Buy | $31.00 | N/A | Maintains | a year ago |
Adial Pharmaceuticals IncADIL | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Dermata Therapeutics IncDRMA | 1 | Strong Buy | $224.00 | N/A | Initiates Coverage On | 2 years ago |
Oncternal Therapeutics IncONCT | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 2 years ago |
9 Meters Biopharma IncNMTR | 1 | Strong Buy | $120.00 | N/A | Assumes | 2 years ago |
Nls Pharmaceutics LtdNLSP | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Lisata Therapeutics IncLSTA | 1 | Strong Buy | $10.00 | N/A | Maintains | 2 years ago |
Cns Pharmaceuticals IncCNSP | 1 | Strong Buy | $300.00 | N/A | Initiates Coverage On | 2 years ago |
Forte Biosciences IncFBRX | 1 | Strong Buy | $90.00 | N/A | Initiates Coverage On | 3 years ago |
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.